Navigation Links
S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/2/2009

SINGAPORE, Dec. 2 /PRNewswire/ -- S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans.

Data will be presented on the clinical results from the Phase 1 dose-escalation trial of SB1518 detailing its safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile in dose levels ranging from 100 to 600 mg. These doses were administered once daily continuously in 28-day cycles in patients with advanced myelofibrosis (MF) and acute myelogenous leukemia (AML). More than 35 patients have been enrolled to date and treated at multiple dose levels ranging from 100-600 mg daily. SB1518 demonstrated promising activity in MF patients. The study generated a positive signal that warrants further investigation.

In an oral presentation, data will be presented from a Phase 1 dose-escalating trial of SB1518 tested in four doses, from 100 to 400 mg per day, in heavily pre-treated relapsed or refractory Hodgkins (HL) and non-Hodgkins lymphoma (NHL) patients. SB1518 was well tolerated with mostly grade 1/2 gastrointestinal side effects. The maximum tolerated dose was not reached in the study and dose escalation is continuing. 15 of 17 treated patients were assessed for tumor response at the eight-week treatment mark. Three patients demonstrated partial and minor responses at the 300 mg dose level and overall 11 patients had stable disease.

"Our clinical findings provide further evidence of SB1518's potential as a viable treatment for myeloproliferative disorders and other hematological malignancies," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "Demonstration of safety, tolerability, and signs of activity in different disease states in our Phase 1 trials, has allowed us to advance SB1518 into Phase 2 clinical trials for further testing of the safety and efficacy of our compound."

Validation
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
2. S*BIO Completes US$26 Million Equity Financing
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
5. Novel Technology Breaks Through Cancer Pain
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
9. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
10. NIST team develops novel method for nanostructured polymer thin films
11. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... , ... uBiome, the leading microbial genomics company, is offering talented researchers with ... 16S laboratory analysis. The goal is to fast-track a study with the greatest potential ... own dashboard, enabling them to view and compare the results of their study, as ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Pistoia Alliance, a ... in life science R&D, has attracted a number of new members from across ... pharmaceutical company joining as a Core member, and DNAnexus and Tessella as Participating ...
(Date:7/6/2015)... , July 6, 2015  Emdeon ... into a definitive agreement to acquire Altegra ... intervention platforms that combine data aggregation and ... capabilities to achieve actionable insights and improved ... combine Altegra Health,s risk adjustment and quality ...
(Date:7/6/2015)... LOS ANGELES , July 6, 2015 ... the establishment of an agreement with Novella Clinical ... of ICT-107 in patients with newly diagnosed glioblastoma. Novella ... clinical trial services to small to mid-sized oncology companies. ... clinical sites in the US, Europe ...
Breaking Biology Technology:uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 2uBiome to Award Grant of up to $100k for Groundbreaking Microbiome Research 3Pistoia Alliance Continues to Attract New Members 2Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... Foundation and NCPA Join Forces to Deliver Patient Care via Single ... ... Mirixa Corporation,and the American Pharmacists Association (APhA) Foundation, the creator of,the ... announced today that they will form a new partnership that will,deliver ...
... 9 CEL-SCI Corporation,(NYSE: CVM ) announced ... new,manufacturing facility for its lead drug Multikine(R). This ... the Multikine that,will be used for CEL-SCI,s pivotal ... untreated head and neck cancer patients, and,subsequently for ...
... Inc., a,privately held biopharmaceutical company, announced today that ... executive vice president and chief,financial officer., "Bob ... 28 years of,financial management experience to Horizon, including ... private companies," said Timothy P.,Walbert, president and chief ...
Cached Biology Technology:Mirixa Corporation and the APhA Foundation Form Partnership 2Mirixa Corporation and the APhA Foundation Form Partnership 3CEL-SCI Takes Delivery of New Manufacturing Facility 2Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer 2
(Date:7/7/2015)... June 30, 2015 ... the addition of the "Capacitive Fingerprint Sensors ... To this date, fingerprint sensing technology is ... fingerprint sensors are well developed. This patent landscape ... The domain of capacitive fingerprint sensors ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... N.J. -- January 31, 2013 -- Deborah E. Wiley, ... Inc. (NYSE: JWa & JWb), announced today that the ... awarded to Dr. Michael Young, Rockefeller University, Dr. Jeffrey ... University. The Wiley Prize is being awarded to ...
... , CHAPEL HILL, N.C. In the last decade, a ... hospital walls, putting everyone at risk of contracting the dangerous ... USA300 contains a chunk of genes not shared by ... genetic material enables the bacteria to survive and persist in ...
... The 12th annual Wiley Prize in Biomedical Sciences ... and Jeffrey Hall and their colleague Michael Young ... molecular mechanisms governing circadian rhythms. "The molecular ... to many biological processes including sleep and wakefulness, ...
Cached Biology News:12th annual Wiley Prize in Biomedical Sciences awarded 212th annual Wiley Prize in Biomedical Sciences awarded 3UNC study may lead to treatments that are effective against all MRSA strains 2Wiley Prize in Biomedical Sciences awarded to Rosbash, Hall and Young 2
... highly purified preparation of the catalytic subunit ... recognizes the identical cleavage site as the ... activity. Novagen&'s enzyme is produced in ... the highest activity available, and is qualified ...
... the Salmonella Common Structural Antigens (CSA) made ... pool of goats immunized with different strains ... reactive to Salmonella and recognizes all Salmonella ... specificity for Group B and D Salmonella ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... The Jouan B4i ventilated and BR4i refrigerated ... and low speed operation at a low sound ... accessories certified for biocontainment. Their AUTO-LOCK rotor exchange ... is ready for use within seconds. ...
Biology Products: